Verteporfin (CL 318952)

For research use only. Not for use in humans.

目录号:S1786 别名: Visudyne 中文名称:维替泊芬

Verteporfin (CL 318952) Chemical Structure

CAS No. 129497-78-5

Verteporfin (CL 318952, Visudyne) 是一种能够抑制YAP-TEAD相互作用的小分子化合物,抑制YAP诱导的肝脏过度生长。同时,它还是一种有效的衍生自卟啉的第二代光敏剂。Verteporfin 是一种自噬抑制剂。Verteporfin 可抑制细胞增殖并诱导凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2760.03 现货
RMB 2607.44 现货
RMB 7928.11 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Verteporfin (CL 318952)发表文献84篇:

产品安全说明书

VDA抑制剂选择性比较

生物活性

产品描述 Verteporfin (CL 318952, Visudyne) 是一种能够抑制YAP-TEAD相互作用的小分子化合物,抑制YAP诱导的肝脏过度生长。同时,它还是一种有效的衍生自卟啉的第二代光敏剂。Verteporfin 是一种自噬抑制剂。Verteporfin 可抑制细胞增殖并诱导凋亡。
靶点
VDA [1]
(Endothelial cells)
YAP/TEAD interaction [3]
()
体外研究

对于穿透组织最好的波长(i.e.,大约700 nm)下的吸收光,Verteporfin比hematoporphyrin大约有效4倍,从而比hematoporphyrin提供了更高的细胞毒性(在人贴壁细胞中10倍以上)。Verteporfin是亲脂性的,与正常细胞或静息细胞相比,更容易被恶性的或激活的细胞摄取。Verteporfin与LDL结合形成一个复合物,随后可能通过LDL受体或者內吞作用被增殖细胞 (例如,新生血管内皮细胞) 摄取。Verteporfin疗法通过血管通道中形成血栓实现新生血管区的血管造影完全闭塞,进而引起选择性血管内皮损伤。Verteporfin疗法选择性诱导可再生的和离体的脉络膜毛细血管闭塞,而不改变覆盖的光感受器或神经节细胞,如光学和电子显微镜所示。[1] HL-60细胞中胱天蛋白酶-3和胱天蛋白酶-9的活化以及PARP的裂解映射出,光存在下,Verteporfin快速使细胞凋亡改变,该改变会被普通半胱天冬酶抑制剂ZVAD.fmk阻断。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL-60 MlT5SpVv[3Srb36gZZN{[Xl? NXPaeI9JhjFyMDDu[{9uVA>? NUnLfJZHTE2VTx?= MWfpcoNz\WG|ZYOgSG5CKG[{YXft[Y51[XSrb36gcIV3\Wy| NVHlbFNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC2NFc4OTBpPkGwOlA4PzFyPD;hQi=>
HL-60 M2Dt[4N6fG:2b4jpZ4l1gSCjc4PhfS=> M4n5S54yODBibnevcWw> MmLySG1UVw>? NGXkdnlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= M4PqfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNkC3O|ExLz5zME[wO|cyODxxYU6=
Jurkat M3TL[GFxd3C2b4Ppd{Bie3OjeR?= M12y[p4zQDBibl2= MYTEUXNQ NFHjU4NqdmS3Y3XzJIEhSmOuLUKt[IVx\W6mZX70JIFxd3C2b4Ppdy=> M1u2VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzMkS1OFE2Lz5zMUK0OVQyPTxxYU6=
RIF-1 NHXDU2tHfW6ldHnvckBie3OjeR?= MoroNUDPxGdxbXy= MVfEUXNQ NVj3[4ZD\GWlcnXhd4V{KG:6eXflckBkd26|dX3weIlwdg>? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZzNUexPEc,OTJ4MUW3NVg9N2F-
RIF-1 NEm4SoxkgXSxdH;4bYNqfHliYYPzZZk> MlTzNUDPxGdxbXy= M1jkTmROW09? MVPk[YNz\WG|ZTD0c{AzOCEEsTC1KUBk\WyuIIP1dpZqfmGu M3LQU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkG1O|E5Lz5zMk[xOVcyQDxxYU6=
SVEC4-10 NFz0dItHfW6ldHnvckBie3OjeR?= Mne3NlAxKG6pL33s MYPEUXNQ MlXIbY5lfWOnczDtbYNzd3S3YoXs[UBl\XCxbInt[ZJqgmG2aX;u NXzZOo1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0OlcyODZpPkG2OFY4OTB4PD;hQi=>
SVEC4-10 NV:1VJk2TnWwY4Tpc44h[XO|YYm= MnnKNlAxKG6pL33s NYHEUZgzTE2VTx?= NYLHU|g4cW6mdXPld{B{fHKnc4OgZYN1cW5iZnni[ZIh\m:{bXH0bY9v MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjR4N{GwOkc,OTZ2NkexNFY9N2F-
ARPE-19 NWfkXlJj[3m2b4TvfIlkcXS7IHHzd4F6 Ml\zglAvOSEQvHevcYw> MlHlSG1UVw>? NEjtbW5{cG:5czDhJIRwe2VvZHXw[Y5l\W62IITvfIlkcXS7 NV7tdoJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5PFc6ODVpPkG2PVg4QTB3PD;hQi=>
ARPE-19 MmPWSpVv[3Srb36gZZN{[Xl? NIjDZ48xNjBzIN88[{9udA>? MU\EUXNQ NGjVSIRqdmO{ZXHz[ZMhXkWJRjDhcoQhemWmdXPld{BRTUSIIHX4dJJme3Orb36= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjl6N{mwOUc,OTZ7OEe5NFU9N2F-
Y-79 MkjBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHT6Z2d,OSEQvHevcYw> MkPySG1UVw>? MX3k[YNz\WG|ZYOgdoV1cW6xYnzhd5RwdWFiY3XscEBxem:uaX\ldoF1cW:w NEj4V|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3PVc3PCd-MUi1O|k4PjR:L3G+
WERI-Rb1 MULHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MYP+NUDPxGdxbXy= M1n3c2ROW09? MkHI[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5OUe2OEc,OTh3N{m3OlQ9N2F-
RB247C3 NIrtV4JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVzHdZpVhjFizsznM41t Ml:2SG1UVw>? Mlfi[IVkemWjc3XzJJJmfGmwb3LsZZN1d22jIHPlcIwheHKxbHnm[ZJifGmxbh?= M{njV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUe5O|Y1Lz5zOEW3PVc3PDxxYU6=
RB355 M3jY[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NU\rUFBLhjFizsznM41t MVHEUXNQ M1rDeoRm[3KnYYPld{Bz\XSrbn;icIF{fG:vYTDj[YxtKHC{b3zp[oVz[XSrb36= Mo\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3OlQoRjF6NUe5O|Y1RC:jPh?=
RB383 NFzNdJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= NVvIO2wzhjFizsznM41t NH;JcZVFVVOR M3\yZoRm[3KnYYPld{Bz\XSrbn;icIF{fG:vYTDj[YxtKHC{b3zp[oVz[XSrb36= MnjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3N{m3OlQoRjF6NUe5O|Y1RC:jPh?=
hFibro M3j3b4N6fG:2b4jpZ4l1gSCjc4PhfS=> NUX3foo4OC53INM1[{9udA>? Ml;iSG1UVw>? MXTk[YNz\WG|ZYOgeoli[mmuaYT5JIJ6KDh4LEWl M2DyNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESxNVE1Lz5{M{S0NVEyPDxxYU6=
pTMC M{DJWoN6fG:2b4jpZ4l1gSCjc4PhfS=> NFPkd5YxNjViwsXnM41t NEf2eZVFVVOR MWnk[YNz\WG|ZYOgeoli[mmuaYT5JIJ6KDl{Lkml MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR2MUGxOEc,OjN2NEGxNVQ9N2F-
hTMC NIHUcHlkgXSxdH;4bYNqfHliYYPzZZk> NHvj[IwxNjViwsXnM41t M17HOmROW09? NEDLd4Jl\WO{ZXHz[ZMhfmmjYnnsbZR6KGK7IEi4Mlkm MoqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEGxNVQoRjJ|NESxNVE1RC:jPh?=
ARPE-19 MYjjfZRwfG:6aXPpeJkh[XO|YYm= MY[wMlUhyrWpL33s NWrTWYVITE2VTx?= NIe0bYhl\WO{ZXHz[ZMhfmmjYnnsbZR6KGK7IEW1MlUm M4XieVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NESxNVE1Lz5{M{S0NVEyPDxxYU6=
Panc-1 M3\hfGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MX:xNEDPxE1? MnXNSG1UVw>? NIXYdIxqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> NFPrSZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC2PVA3QSd-MkSwOlkxPjl:L3G+
MIA PaCa-2 NV7rVYk4T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFjJXVgyOCEQvF2= NYG1PHdyTE2VTx?= MnXEbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u NUnjNGlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlkxPjlpPkK0NFY6ODZ7PD;hQi=>
BxPC-3 NUfkd4ljT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NFzPNYUyOCEQvF2= NWLD[G94TE2VTx?= NYeyPVl6cW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHl? M4Ppc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2ME[5NFY6Lz5{NEC2PVA3QTxxYU6=
SU86.86 MUDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWjqcZBwOTBizszN MnHZSG1UVw>? NGDTWlJqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h[2:vcHzleIVtgQ>? NX7xNWluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlkxPjlpPkK0NFY6ODZ7PD;hQi=>
MCF-7 Ml\kRZV1d3CqYXf5JIF{e2G7 NEixRXQyOCEQvF2= NILNWWNFVVOR M1H6eIlvcGmkaYTzJIdmdWOrdHHibY5mNWmwZIXj[YQh[XW2b4DoZYd6 MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4OUC2PUc,OjRyNkmwOlk9N2F-
WERI NYfJTZVoT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= Mnj0glExKM7:Zz;tcC=> MWPEUXNQ M3viVYlvcGmkaYTzJIdzd3e2aDDv[kBz\XSrbn;icIF{fG:vYTDj[Yxtew>? NUTDOmxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|cyPDJpPkK0PFM4OTR{PD;hQi=>
WERI MmK5SpVv[3Srb36gZZN{[Xl? M4TDOZ4yOCEQvHevcYw> MmT0SG1UVw>? NU\nNHZD[myxY3vzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25? NGPqcJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizO|E1Oid-MkS4N|cyPDJ:L3G+
Y-79 M175d2Z2dmO2aX;uJIF{e2G7 MlLmglExKM7:Zz;tcC=> MXvEUXNQ NFmwW2tjdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdg>? M321U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEO3NVQzLz5{NEizO|E1OjxxYU6=
Y-79 NV7ac|Q{TnWwY4Tpc44h[XO|YYm= NGT1cWZ,OTBizsznM41t MVzEUXNQ M2PkNoFn\mWldIOgXWFRNVSHQVSgdJJwfG9vb37jc4dmdmVicHH0bJdigQ>? NX;jSplPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|cyPDJpPkK0PFM4OTR{PD;hQi=>
Y-79 NXu5dm5xTnWwY4Tpc44h[XO|YYm= NUDqc5RThjFyIN88[{9udA>? Ml7rSG1UVw>? MYDkc5dvNXKnZ4XsZZRmeyCybIXybZBwfGWwY4mgcYFzc2W{IF;DWE01 MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|N{G0Nkc,OjR6M{exOFI9N2F-
Phototoxicity assay MlvjRlE3TjFy M4PV[|I1KGi{cx?= M4HCRmlEPTBiPTCxMlA4KM7:TR?= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF|NkO4PUc,OjdzM{[zPFk9N2F-
Phototoxicity assay NXL0UlZvSjF4RkGw MWeyOEBpenN? NWPOOolTUUN3MDC9JFEvOiEQvF2= NEDiPFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzOlM5QSd-MkexN|Y{QDl:L3G+
Phototoxicity assay NVnTV4FLSTN5NR?= M3nkPFI1KGi{cx?= NWXYXXBYUUN3MDC9JFIvODZizszN M{PDUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=
Dark toxicity assay MX\CNVZHOTB? NECzdnk1QCCqcoO= M{\5T2lEPTBiPTCyOE46OiEQvF2= M1fk[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUO2N|g6Lz5{N{GzOlM5QTxxYU6=
Dark toxicity assay M2jPZmIyPkZzMB?= M17ITlQ5KGi{cx?= MVzJR|UxKD1iMkWuNFMh|ryP MkHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{[zPFkoRjJ5MUO2N|g6RC:jPh?=
Dark toxicity assay Ml:5RVM4PQ>? M2K2T|Q5KGi{cx?= MWHJR|UxKD1iM{[uN|Mh|ryP NEnTW3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzOlM5QSd-MkexN|Y{QDl:L3G+
qHTS assay MoLtWGM{Og>? NXvW[I1JeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGTDN|Ih[2WubIO= NEHEOZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay MnH0WU0zKE:V NYLaSZNkeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=> M4X2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay MnvRRVY4Ow>? NV;yNlk2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MlHlSGFQYQ>? MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NXfTfVloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay NYLKdJpNW2Gxcz2y NF;6XoxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz MorTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MX;CWE0{Pw>? NW[yWlVZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz M{SwZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NULGN|ZoWkR? NYX5Rm1IeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| M4jBNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NHX6WIJUUy2QLWPI NVXEWZpneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> MoKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MnmzRnQuOTJ? MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? M1z5eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay NF7sTppOTyB4MzCoOk1VTyCUKR?= MkK1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NGHnNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay M1\IdG9JWy13MB?= MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NH\mNm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NWW0RlViWmh2MR?= M2nmUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
qHTS assay NGq2Vm9UUi2JQl2y M4rQeZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz MlTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay MXzTT{1PNU2F Mk\IdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= NI\VOWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
qHTS assay NIe2NlFNSU5vNR?= NGTkTJZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= Mn[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Antitumor assay MWHCNVZHOTB? MUKyJI1oN2up NH;lenEzKGi{cx?= NXHCRog5SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhSjF4RkGwJINmdGy|IHntdIxidnSnZDDpckBEPTeETD:2JI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFIhdWdxa3esJIl3KGGmbXnubZN1\XKnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhcXK{YXTpZZRqd25id3n0bEBt[XOncjDheEAyPTBiSj;jcUczKG[xcjCxNEBucW6| NInSWJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzOlM5QSd-MkexN|Y{QDl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-S6(S240/244) / p-4EBP1(S65); 

PubMed: 28202507     


KLE, EFE184 and NOU-1 were treated with Verteporfin (0.1 μM, 0.3 μM). After 36h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.

c-Myc / Bcl-2; 

PubMed: 29416644     


In CAL27 cell lines, the expression of BCL-2 and C-MYC proteins decreased with the increase of Verteporfin concentration. The presented columns are given as the means ± SD. *p < 0.05, **P < 0.01, ***p < 0.001.

ECAD / Vimentin / Sox2 / CD44 / CD133; 

PubMed: 30467925     


Yes-associated protein 1 (YAP1), E-cadherin, vimentin (epithelial-mesenchymal transition [EMT] pathway), SOX2 CD44 and CD133 (autophagy markers) were detected by western blot in control, verteporfin (1 μmol/L) and verteporfin + 231-taxol (0.5 μmol/L) resistance groups.

beta-catenin; 

PubMed: 28202507     


KLE, EFE184, NOU-1 and SKUT-2 were treated with 3 μM Verteporfin. After 24h, cell lysates were western blotted with indicated antibodies. Bands are from one of three independent experiments.

28202507 29416644 30467925
Growth inhibition assay
Cell viability; 

PubMed: 28042502     


A: Cell viability was determined by MTS assay after the UM cells were exposed to verteporfin for 72 hours. B: After treated with various concentrations of verteporfin for 24 hours, the UM cells (e.g., 92.1, Mel 270, Omm 1, Omm 2.3) were seeded in drug-free soft agar culture for 14 days. Colonies were counted. 

28042502
Immunofluorescence
YAP1; 

PubMed: 30254296     


Treatment of U343 cells with 5 μM VP between 1-8 h in both 21% and 1% O2 induced morphological changes. Scale bar represents 10 µm. VP: Verteporfin

Calreticulin; 

PubMed: 30254296     


Calreticulin (CRT) significantly increased in VP-treated (5 µM, 2 h) U87 cells in both 21% and 1% O2 indicating likely ER stress.

p-YAP(Y357); 

PubMed: 28404908     


Confocal images of HEC-1-B cells and organoids which were subjected to immunofluorescence detection of A. YAP and B. phospho-YAP after VP treatment. YAP and phospho-YAP are conjugated with goat anti-mouse and goat anti-rabbit Alexa flour secondary antibodies respectively. (A) Upper panel bar=63x and lower panel bar = 20x. (B) Upper panel bar=63x and lower panel bar = 20x.

30254296 28404908
体内研究 Verteporfin可用于脉络膜血管和CNV的血管可视化,这表明光敏剂在猴子的实验性CNV中快速集聚。Verteporfin在建立的兔子眼睛的脉络膜脉管系统,RPE,以及光感受器中迅速积累。在小鼠体内,静脉注射3小时后,Verteporfin达到最大组织水平,随后在24小时内迅速下降。Verteporfin在体内代谢为活性较低的形式,并且迅速清除,主要通过粪便排泄,一小部分通过尿液排泄。Verteporfin疗法有效的选择性阻止了荧光染料从实验性诱导的猴子CNV的泄漏。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 100 mg/mL (139.12 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 718.79
化学式

C41H42N4O8

CAS号 129497-78-5
储存条件 3年-20°C 粉状
2年-80°C 溶于溶剂 (避光)
别名 Visudyne

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04590664 Recruiting Drug: Verteporfin Glioblastoma|Recurrent Glioblastoma Emory University|National Cancer Institute (NCI) January 15 2021 Phase 1|Phase 2
NCT03797547 Active not recruiting Other: AFLIBERCEPT Myopic Choroidal Neovascularisation Poitiers University Hospital June 22 2018 --
NCT01846273 Completed Drug: Ranibizumab|Drug: Verteporfin PDT|Drug: Sham PDT Age-related Macular Degeneration|Polypoidal Choroidal Vasculopathy Novartis Pharmaceuticals|Novartis August 7 2013 Phase 4
NCT00423189 Terminated Drug: Ranibizumab (Lucentis)|Drug: 0.5mg ranibizumab Age-Related Macular Degeneration David M. Brown M.D.|Novartis Pharmaceuticals|Greater Houston Retina Research January 2007 Phase 4
NCT00403442 Terminated Device: Verteporfin Therapy/ Drug: Bevacizumab Macular Degeneration Vitreous -Retina- Macula Consultants of New York|QLT Inc. September 2006 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

VDA Signaling Pathway Map

相关VDA产品

Tags: 购买Verteporfin (CL 318952) | Verteporfin (CL 318952) ic50 | Verteporfin (CL 318952)价格 | Verteporfin (CL 318952) DMSO溶解度 | 采购Verteporfin (CL 318952) | Verteporfin (CL 318952)生产 | Verteporfin (CL 318952) 小鼠 | Verteporfin (CL 318952)化学结构 | Verteporfin (CL 318952)分子量 | Verteporfin (CL 318952) molecular weight | Verteporfin (CL 318952)说明书 | Verteporfin (CL 318952)供应商 | Verteporfin (CL 318952)体内 | Verteporfin (CL 318952)细胞系 | Verteporfin (CL 318952)浓度 | Verteporfin (CL 318952) nmr | Verteporfin (CL 318952)核磁 | Verteporfin (CL 318952)半数抑制浓度 | Verteporfin (CL 318952)体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID